Latest filing published 23 Mar 2026 for Novonesis (Novozymes A/S), €2.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Morten Enggaard Rasmussen: trading record in brief
All filings by Morten Enggaard Rasmussen on record concern Novonesis (Novozymes A/S). Between 22 August 2025 and 23 March 2026, the trades on record add up to 4 filings.
Purchases make up the whole of the open-market record (3 purchases, €59k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2026 alone, the filings show 1 purchase and no sales.
A typical purchase (the median) is worth €21k. None of the 3 purchases we analysed coincided with buying by another insider of the same company within 30 days.
On 23 March 2026 came the latest disclosure, an open-market purchase for €2 in Novonesis (Novozymes A/S). Half of the filings or more reach the Finanstilsynet DK feed on the day of the trade. For comparison, MAR article 19 gives managers three business days to notify a trade. Every figure here comes from the filings published by Finanstilsynet DK and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Morten Enggaard Rasmussen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 4 shares@ DKK 3.000.0% of flowShareXCSEISIN DK0060336014DK:1428126Canonical exit: 21 Jun 2026 (T+90)
- 725 shares@ DKK 347.400.0% of flowShareNasdaqISIN DK0060336014DK:1425698
- 380 shares@ DKK 418.100.0% of flowShareNasdaq XCSEISIN DK0060336014DK:1399510Canonical exit: 5 Feb 2026 (T+90)
- 716 shares@ DKK 390.000.0% of flowShareNasdaq CopenhagenISIN DK0060336014DK:1384879Canonical exit: 20 Nov 2025 (T+90)
4 of 4 declarations